According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest paper that was published a few days ago paper has been selected by the editors of…READ MORE
March 24, 2020
Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test. Rashid Bux, President and CEO, says, “This latest publication demonstrates our ability to further leverage our international team of leading clinicians, scientists, researchers and data scientists in discovery […]
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.